Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets
Abstract Reducing circulating lipid levels is the centerpiece of strategies for preventing and treating atherosclerotic cardiovascular disease (ASCVD). Despite many available lipid-lowering medications, a substantial residual cardiovascular risk remains. Current clinical guidelines focus on plasma l...
| Príomhchruthaitheoirí: | , , , , , , , |
|---|---|
| Formáid: | Alt |
| Teanga: | English |
| Foilsithe / Cruthaithe: |
BMC
2024-01-01
|
| Sraith: | Lipids in Health and Disease |
| Ábhair: | |
| Rochtain ar líne: | https://doi.org/10.1186/s12944-023-01993-y |
| _version_ | 1827381986441822208 |
|---|---|
| author | Jingfei Chen Zhenfei Fang Qin Luo Xiao Wang Mohamad Warda Avash Das Federico Oldoni Fei Luo |
| author_facet | Jingfei Chen Zhenfei Fang Qin Luo Xiao Wang Mohamad Warda Avash Das Federico Oldoni Fei Luo |
| author_sort | Jingfei Chen |
| collection | DOAJ |
| description | Abstract Reducing circulating lipid levels is the centerpiece of strategies for preventing and treating atherosclerotic cardiovascular disease (ASCVD). Despite many available lipid-lowering medications, a substantial residual cardiovascular risk remains. Current clinical guidelines focus on plasma levels of low-density lipoprotein (LDL). Recent attention has been given to very low-density lipoprotein (VLDL), the precursor to LDL, and its role in the development of coronary atherosclerosis. Preclinical investigations have revealed that interventions targeting VLDL production or promoting VLDL metabolism, independent of the LDL receptor, can potentially decrease cholesterol levels and provide therapeutic benefits. Currently, methods, such as mipomersen, lomitapide, and ANGPTL3 inhibitors, are used to reduce plasma cholesterol and triglyceride levels by regulating the lipidation, secretion, and metabolism of VLDL. Targeting VLDL represents an avenue for new lipid-lowering strategies. Interventions aimed at reducing VLDL production or enhancing VLDL metabolism, independent of the LDL receptor, hold promise for lowering cholesterol levels and providing therapeutic benefits beyond LDL in the management of ASCVD. |
| first_indexed | 2024-03-08T14:12:56Z |
| format | Article |
| id | doaj.art-2b9755b36d6c487a9cbfacba3ea05fc9 |
| institution | Directory Open Access Journal |
| issn | 1476-511X |
| language | English |
| last_indexed | 2024-03-08T14:12:56Z |
| publishDate | 2024-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Lipids in Health and Disease |
| spelling | doaj.art-2b9755b36d6c487a9cbfacba3ea05fc92024-01-14T12:34:48ZengBMCLipids in Health and Disease1476-511X2024-01-0123111110.1186/s12944-023-01993-yUnlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targetsJingfei Chen0Zhenfei Fang1Qin Luo2Xiao Wang3Mohamad Warda4Avash Das5Federico Oldoni6Fei Luo7Reproductive Medicine Center, Department of Obstetrics and Gynecology, Research Institute of Blood Lipid and Atherosclerosis, The Second Xiangya Hospital, Central South UniversityResearch Institute of Blood Lipid and Atherosclerosis, the Second Xiangya Hospital, Central South UniversityResearch Institute of Blood Lipid and Atherosclerosis, the Second Xiangya Hospital, Central South UniversityState Key Laboratory of Membrane Biology, Peking UniversityDepartment of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine, Cairo UniversityDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical SchoolDepartment of Molecular Genetics, University of Texas Southwestern Medical CenterResearch Institute of Blood Lipid and Atherosclerosis, the Second Xiangya Hospital, Central South UniversityAbstract Reducing circulating lipid levels is the centerpiece of strategies for preventing and treating atherosclerotic cardiovascular disease (ASCVD). Despite many available lipid-lowering medications, a substantial residual cardiovascular risk remains. Current clinical guidelines focus on plasma levels of low-density lipoprotein (LDL). Recent attention has been given to very low-density lipoprotein (VLDL), the precursor to LDL, and its role in the development of coronary atherosclerosis. Preclinical investigations have revealed that interventions targeting VLDL production or promoting VLDL metabolism, independent of the LDL receptor, can potentially decrease cholesterol levels and provide therapeutic benefits. Currently, methods, such as mipomersen, lomitapide, and ANGPTL3 inhibitors, are used to reduce plasma cholesterol and triglyceride levels by regulating the lipidation, secretion, and metabolism of VLDL. Targeting VLDL represents an avenue for new lipid-lowering strategies. Interventions aimed at reducing VLDL production or enhancing VLDL metabolism, independent of the LDL receptor, hold promise for lowering cholesterol levels and providing therapeutic benefits beyond LDL in the management of ASCVD.https://doi.org/10.1186/s12944-023-01993-yAtherosclerotic cardiovascular diseaseVery low-density lipoproteinLow-density lipoproteinLDL receptor-independent pathway |
| spellingShingle | Jingfei Chen Zhenfei Fang Qin Luo Xiao Wang Mohamad Warda Avash Das Federico Oldoni Fei Luo Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets Lipids in Health and Disease Atherosclerotic cardiovascular disease Very low-density lipoprotein Low-density lipoprotein LDL receptor-independent pathway |
| title | Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets |
| title_full | Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets |
| title_fullStr | Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets |
| title_full_unstemmed | Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets |
| title_short | Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets |
| title_sort | unlocking the mysteries of vldl exploring its production intracellular trafficking and metabolism as therapeutic targets |
| topic | Atherosclerotic cardiovascular disease Very low-density lipoprotein Low-density lipoprotein LDL receptor-independent pathway |
| url | https://doi.org/10.1186/s12944-023-01993-y |
| work_keys_str_mv | AT jingfeichen unlockingthemysteriesofvldlexploringitsproductionintracellulartraffickingandmetabolismastherapeutictargets AT zhenfeifang unlockingthemysteriesofvldlexploringitsproductionintracellulartraffickingandmetabolismastherapeutictargets AT qinluo unlockingthemysteriesofvldlexploringitsproductionintracellulartraffickingandmetabolismastherapeutictargets AT xiaowang unlockingthemysteriesofvldlexploringitsproductionintracellulartraffickingandmetabolismastherapeutictargets AT mohamadwarda unlockingthemysteriesofvldlexploringitsproductionintracellulartraffickingandmetabolismastherapeutictargets AT avashdas unlockingthemysteriesofvldlexploringitsproductionintracellulartraffickingandmetabolismastherapeutictargets AT federicooldoni unlockingthemysteriesofvldlexploringitsproductionintracellulartraffickingandmetabolismastherapeutictargets AT feiluo unlockingthemysteriesofvldlexploringitsproductionintracellulartraffickingandmetabolismastherapeutictargets |